ArticleFrontiers in immunology2026
Top 100 most-cited articles on NLRP3 (2000-2024): a retrospective analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Advances in NLRP3 inflammasome research in viral infections: evolution, trends, and future directions.Frontiers in cellular and infection microbiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to identify and analyze the top 100 most-cited articles in the NLRP3 research field to uncover research trends, key contributors, and collaborative networks, thereby providing insights into the development and future directions of NLRP3 inflammasome studies. Methods: A comprehensive search was conducted using the Web of Science and PubMed from January 2000 to December 2024. Search terms included "NLRP3" and related nomenclature. Articles were screened and sorted by citation frequency, and the top 100 were selected for detailed analysis of citations, authors, countries, institutions, journals, funding sources, and research fields. Results: These articles covered 20 publishers, 218 funds, 19 research fields, 811 authors, 25 countries, 46 journals, and 224 institutions. Among these authors, Latz E published the largest number of articles and had the highest citation frequency and the strongest co-authorship ties. Among these countries, USA published the largest number of articles and had the highest citation frequency and the strongest co-authorship ties. Among these institutions, University of Massachusetts published the largest number of articles and had the highest citation frequency and the strongest co-authorship ties. Among these journals, Nature published the largest number of articles and had the highest citation frequency and the strongest co-authorship ties. Conclusion: This retrospective analysis highlights the growing interest and interdisciplinary nature of NLRP3 inflammasome research. The USA, leading institutions, and high-impact journals play central roles in shaping the field. Future research is expected to focus on translational applications, including the development of NLRP3 inhibitors and activators, and exploring NLRP3 functions in non-immune cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.